Literature DB >> 15647404

Interaction of warfarin with drugs, natural substances, and foods.

David J Greenblatt1, Lisa L von Moltke.   

Abstract

Variability in the anticoagulant response to warfarin is an ongoing clinical dilemma. Fluctuations in dietary vitamin K are an important source of variance, and the need for constancy in vitamin K intake is routinely emphasized for warfarin-treated patients. Anticoagulant response is also influenced by a number of drugs that induce or inhibit warfarin metabolism, as well as by genetic polymorphisms that may modulate expression or activity of CYP2C9, the isoform mediating clearance of S-warfarin. The possible role of dietary factors other than vitamin K, as well as of herbal medicines or supplements as contributors to the instability of anticoagulation in warfarin-treated patients, has received recent attention. St. John's wort and possibly some ginseng formulations may have the potential to diminish warfarin anticoagulation, apparently by inducing CYP2C9 activity. Otherwise, there is no reliable evidence to indicate that any dietary component (other than vitamin K) or any herbal product has an effect on the anticoagulant response to warfarin. Scientific conclusions on this important therapeutic issue should be based on valid scientific data rather than unvalidated case reports.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647404     DOI: 10.1177/0091270004271404

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  40 in total

Review 1.  Balancing ischaemia and bleeding risks with novel oral anticoagulants.

Authors:  Usman Baber; Ioannis Mastoris; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2014-11-04       Impact factor: 32.419

2.  Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients.

Authors:  Chadwick K Mellen; Marjorie Ford; Joseph P Rindone
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 3.  [Oral anticoagulation and risk of bleeding in elderly patients - the aspect of polypharmacy].

Authors:  Regina E Roller; Bernhard Iglseder; Peter Dovjak; Monika Lechleitner; Ulrike Sommeregger; Ursula Benvenuti-Falger; Ronald Otto; Birgit Böhmdorfer; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Drug interactions with warfarin: what clinicians need to know.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2007-08-14       Impact factor: 8.262

6.  Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study.

Authors:  Terhi Launiainen; Antti Sajantila; Ilpo Rasanen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2009-09-25       Impact factor: 2.953

7.  Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.

Authors:  Rene A Braeckman; William G Stirtan; Paresh N Soni
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

8.  Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Authors:  Tetz C Lee; Min Qian; Gregory Y H Lip; Marco R Di Tullio; Susan Graham; Douglas L Mann; Koki Nakanishi; John R Teerlink; Ronald S Freudenberger; Ralph L Sacco; J P Mohr; Arthur J Labovitz; Piotr Ponikowski; Dirk J Lok; Conrado Estol; Stefan D Anker; Patrick M Pullicino; Richard Buchsbaum; Bruce Levin; John L P Thompson; Shunichi Homma; Siqin Ye
Journal:  Am J Cardiol       Date:  2018-06-04       Impact factor: 2.778

9.  A cross-sectional study of the Anticoagulation Clinic in RIPAS Hospital, Brunei.

Authors:  Linda Y Y Lim; Vui Heng Chong; Nallathamby Rajendran; Wai See Wong
Journal:  J Thromb Thrombolysis       Date:  2008-07-30       Impact factor: 2.300

10.  Ginsenosides protect striatal neurons in a cellular model of Huntington's disease.

Authors:  Jun Wu; Hye Kyoung Jeong; Sarah Elizabeth Bulin; Sung Won Kwon; Jeong Hill Park; Ilya Bezprozvanny
Journal:  J Neurosci Res       Date:  2009-06       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.